Related Experiment Videos
[Ursodeoxycholic acid. Physical properties and hepatoprotective activity]
1INSERM, Marseille, France.
Pathologie-Biologie
|June 1, 1991
Summary
Ursodeoxycholic acid may benefit cystic fibrosis patients with liver issues. This hydrophilic bile acid shows promise in preventing liver damage caused by hydrophobic bile acids in animal models.
Area of Science:
- Hepatology
- Gastroenterology
- Biochemistry
Background:
- Cystic fibrosis (CF) patients can develop liver disease due to bile duct obstruction by mucus plugs.
- Hydrophobic bile acids, like chenodeoxycholic acid, accumulate and cause cholestasis and biliary cirrhosis in CF patients.
- Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with distinct physicochemical properties compared to hydrophobic bile acids.
Purpose of the Study:
- To investigate the potential therapeutic effects of ursodeoxycholic acid (UDCA) in managing hepatobiliary disorders associated with cystic fibrosis (CF).
Main Methods:
- Comparison of physicochemical characteristics between UDCA and chenodeoxycholic acid.
- Evaluation of UDCA's effects on bile excretion and cholestasis in animal models challenged with hydrophobic bile salts.
Main Results:
- UDCA exhibits higher critical micellar concentration and lower surface activity than chenodeoxycholic acid.
- UDCA micelles solubilize less lecithin and cholesterol.
- Animal studies demonstrated that UDCA increases bile excretion and prevents cholestasis and cytolysis induced by hydrophobic bile salts.
Conclusions:
- The distinct properties of UDCA suggest its potential efficacy in treating liver complications in cystic fibrosis patients.
- UDCA therapy may offer a beneficial approach to mitigate the hepatobiliary consequences of CF.